Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Retin-A

×

Overview

What is Retin-A?

RETIN-A Gel, Cream and Liquid, containing tretinoin are used for the topical treatment of acne vulgaris. RETIN-A Gel contains tretinoin (retinoic acid, vitamin A acid) in either of two strengths, 0.025% or 0.01% by weight, in a gel vehicle of butylated hydroxytoluene, hydroxypropyl cellulose and alcohol (denatured with butyl alcohol and brucine sulfate) 90% w/w. RETIN-A (tretinoin) Cream contains tretinoin in either of three strengths, 0.1%, 0.05%, or 0.025% by weight, in a hydrophilic cream vehicle of stearic acid, isopropyl myristate, polyoxyl 40 stearate, stearyl alcohol, xanthan gum, sorbic acid, butylated hydroxytoluene, and purified water. RETIN-A Liquid contains tretinoin 0.05% by weight, polyethylene glycol 400, butylated hydroxytoluene and alcohol (denatured with butyl alcohol and brucine sulfate) 55%. Chemically, tretinoin is retinoic acid and has the following structure:



What does Retin-A look like?



What are the available doses of Retin-A?

Sorry No records found.

What should I talk to my health care provider before I take Retin-A?

Sorry No records found

How should I use Retin-A?

RETIN-A is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

RETIN-A Gel, Cream or Liquid should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Liquid: The liquid may be applied using a fingertip, gauze pad, or cotton swab. If gauze or cotton is employed, care should be taken not to oversaturate it to the extent that the liquid would run into areas where treatment is not intended. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient.

Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment.

Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance.

During the early weeks of therapy, an exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy.

Therapeutic results should be noticed after two to three weeks but more than six weeks of therapy may be required before definite beneficial effects are seen.

Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms.

Patients treated with RETIN-A (tretinoin) acne treatment may use cosmetics, but the area to be treated should be cleansed thoroughly before the medication is applied.


What interacts with Retin-A?

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.



What are the warnings of Retin-A?

Sorry No Records found


What are the precautions of Retin-A?

General:

RETIN-A (tretinoin) acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, discontinue use temporarily, or discontinue use altogether. Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.

Drug Interactions:

Carcinogenesis:

Pregnancy:

Oral

Topical

Nursing Mothers:

GELS ARE FLAMMABLE.


What are the side effects of Retin-A?

The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper or hypopigmentation has been reported with repeated application of RETIN-A. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with RETIN-A. To date, all adverse effects of RETIN-A have been reversible upon discontinuance of therapy (see ).


What should I look out for while using Retin-A?

Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.


What might happen if I take too much Retin-A?

If medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling, or discomfort may occur. Oral ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A


How should I store and handle Retin-A?

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].RETIN-A (tretinoin) is supplied as:Storage Conditions:ORTHO DERMATOLOGICALDivision of Ortho-McNeilPharmaceutical, Inc.Skillman, New Jersey 08558©OMP 2001 Revised February 2001 Printed in U.S.A. 643-10-490-9RETIN-A (tretinoin) is supplied as:Storage Conditions:ORTHO DERMATOLOGICALDivision of Ortho-McNeilPharmaceutical, Inc.Skillman, New Jersey 08558©OMP 2001 Revised February 2001 Printed in U.S.A. 643-10-490-9RETIN-A (tretinoin) is supplied as:Storage Conditions:ORTHO DERMATOLOGICALDivision of Ortho-McNeilPharmaceutical, Inc.Skillman, New Jersey 08558©OMP 2001 Revised February 2001 Printed in U.S.A. 643-10-490-9RETIN-A (tretinoin) is supplied as:Storage Conditions:ORTHO DERMATOLOGICALDivision of Ortho-McNeilPharmaceutical, Inc.Skillman, New Jersey 08558©OMP 2001 Revised February 2001 Printed in U.S.A. 643-10-490-9RETIN-A (tretinoin) is supplied as:Storage Conditions:ORTHO DERMATOLOGICALDivision of Ortho-McNeilPharmaceutical, Inc.Skillman, New Jersey 08558©OMP 2001 Revised February 2001 Printed in U.S.A. 643-10-490-9RETIN-A (tretinoin) is supplied as:Storage Conditions:ORTHO DERMATOLOGICALDivision of Ortho-McNeilPharmaceutical, Inc.Skillman, New Jersey 08558©OMP 2001 Revised February 2001 Printed in U.S.A. 643-10-490-9RETIN-A (tretinoin) is supplied as:Storage Conditions:ORTHO DERMATOLOGICALDivision of Ortho-McNeilPharmaceutical, Inc.Skillman, New Jersey 08558©OMP 2001 Revised February 2001 Printed in U.S.A. 643-10-490-9


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.

Non-Clinical Toxicology
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

The concurrent administration of allopurinol and ampicillin increases substantially the incidence of skin rashes in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.

General:

RETIN-A (tretinoin) acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, discontinue use temporarily, or discontinue use altogether. Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition.

Drug Interactions:

Carcinogenesis:

Pregnancy:

Oral

Topical

Nursing Mothers:

GELS ARE FLAMMABLE.

The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper or hypopigmentation has been reported with repeated application of RETIN-A. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with RETIN-A. To date, all adverse effects of RETIN-A have been reversible upon discontinuance of therapy (see ).

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).